Updated options for liver-limited metastatic colorectal cancer

Clinical Colorectal Cancer

Volumn 7, Issue SUPPL. 2, 2008, Pages

  Alberts, Steven R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Conversion therapy; Epidermal growth factor inhibitors; Hepatic artery infusion; Liver metastases; Perioperative chemotherapy

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLOXURIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DIARRHEA; DRUG MEGADOSE; FATTY LIVER; HISTOPATHOLOGY; HUMAN; LIVER METASTASIS; LIVER RESECTION; LONG TERM CARE; NEUROTOXICITY; NEUTROPENIA; PERIOPERATIVE PERIOD; PROGNOSIS; REVIEW; TREATMENT RESPONSE; COLORECTAL TUMOR; HEPATIC ARTERY; INTRAARTERIAL DRUG ADMINISTRATION; LIVER TUMOR; METASTASIS; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; PERIOPERATIVE CARE;

EID: 58949104198     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2008.s.009     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Jessup JM, Stewart AK, Menck HR. The National Cancer Data Base report on patterns of care for adenocarcinoma of the rectum, 1985-95. Cancer 1998; 83:2408-18.
3. Jessup JM, McGinnis LS, Steele GD Jr, et al. The National Cancer Data Base. Report on colon cancer. Cancer 1996; 78:918-26.
4. Ohlsson B, Palsson B. Follow-up after colorectal cancer surgery. Acta Oncologica 2003; 42:816-26.
5. Weiss L, Grundmann E, Torhorst J, et al. Haematogenous metastatic patterns in colonic carcinoma: an analysis of 1541 necropsies. J Pathol 1986; 150:195-203.
6. Catell RB. Successful removal of liver metastasis from a carcinoma of the rectum. Lahey Clinic Bull 1940; 2:7-10.
7. Wilson SM, Adson MA. Surgical treatment of hepatic metastases from colorectal cancer. Arch Surg 1976; 111:330-4.
8. Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230:309-18; discussion, 18-21.
9. Garden OJ, Rees M, Poston GJ, et al. Guidelines for resection of colorectal cancer liver metastases. Gut 2006; 55(suppl 3):iii1-8.
10. Poston GJ, Adam R, Alberts S, et al. OncoSurge: a strategy for improving resect- ability with curative intent in metastatic colorectal cancer. J Clin Oncol 2005; 23:7125-34.
11. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring systems? Ann Surg 2007; 246:183-91.
12. Adam R, Avisar E, Ariche A, et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001; 8:347-53.
13. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unre- sectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999; 10:663-9.
14. Rivoire M, De Cian F, Meeus P, et al. Combination of neoadjuvant chemotherapy with cryotherapy and surgical resection for the treatment of unresectable liver metastases from colorectal carcinoma. Cancer 2002; 95:2283-92.
15. Bismuth H, Adam R, Levi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224:509-20; discussion, 20-2.
16. Alberts SR, Horvath WL, Sternfeld WC, et al. Oxaliplatin, fluorouracil, and leu- covorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study. J Clin Oncol 2005; 23:9243-9.
17. Pozzo C, Basso M, Cassano A, et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004; 15:933-9.
18. Falcone A, Ricci S, Brunetti I, et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25:1670-6.
19. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:2311-9.
20. Tabernero J, Van Cutsem E, Diaz-Rubio E, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2007; 25:5225-32.
21. Adam R, Aloia T, Levi F, et al. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemictherapy. J Clin Oncol 2007; 25:4593-602.
22. Giantonio BJ, Catalano PJ, Meropol NJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated meta- static colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25:1539-44.
23. Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer 2007; 7:91.
24. Diaz Rubio E, Tabernero J, van Cutsem E, et al. Cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer: an international phase II study. J Clin Oncol 2005; 23:254s (Abstract 3535).
25. Kemeny N, Jarnagin W, Paty P, et al. Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol 2005; 23:4888-96.
26. Leonard GD, Brenner B, Kemeny NE. Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma. J Clin Oncol 2005; 23:2038-48.
27. Allen PJ, Kemeny N, Jarnagin W, et al. Importance of response to neoadjuvant chemotherapy in patients undergoing resection of synchronous colorectal liver metastases. J Gastrointest Surg 2003; 7:109-15; discussion, 16-7.
28. Taieb J, Artru P, Paye F, et al. Intensive systemic chemotherapy combined with surgery for metastatic colorectal cancer: results of a phase II study. J Clin Oncol 2005; 23:502-9.
29. Wein A, Riedel C, Bruckl W, et al. Neoadjuvant treatment with weekly high-dose 5-fluorouracil as 24-hour infusion, folinic acid and oxaliplatin in patients with primary resectable liver metastases of colorectal cancer. Oncology 2003; 64:131-8.
30. Benoist S, Brouquet A, Penna C, et al. Complete response of colorectal liver metas tases after chemotherapy: does it mean cure? J Clin Oncol 2006; 24:3939-45.
31. Fernandez FG, Ritter J, Goodwin JW, et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 2005; 200:845-53.
32. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steato- hepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006; 24:2065-72.
33. Aloia T, Sebagh M, Plasse M, et al. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 2006; 24:4983-90.
34. Portier G, Elias D, Bouche O, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006; 24:4976-82.
35. Niederhuber JE, Ensminger W, Gyves J, et al. Regional chemotherapy of colorec- tal cancer metastatic to the liver. Cancer 1984; 53:1336-43.
36. Martin JK, O'Connell MJ, Wieand HS, et al. Intra-arterial floxuridine vs systemic fluorouracil for hepatic metastases from colorectal cancer. A randomizedtrial. Arch Surg 1990; 125:1022-7.
37. O'Connell MJ, Nagorney DM, Bernath AM, et al. Sequential intrahepatic fluorodeoxyuridine and systemic fluorouracil plus leucovorin for the treatment of metastatic colorectal cancer confined to the liver. J Clin Oncol 1998; 16:2528-33.
38. Kemeny N, Huang Y, Cohen AM, et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Engl J Med 1999; 341:2039-48.
39. Kemeny NE, Gonen M. Hepatic arterial infusion after liver resection. N Engl J Med 2005; 352:734-5.
40. Kemeny MM, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metas- tases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol 2002; 20:1499-505.
41. Lorenz M, Muller HH, Schramm H, et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. German Cooperative on Liver Metastases (Arbeitsgruppe Lebermetastasen). Ann Surg 1998; 228:756-62.
42. Nordlinger B, Sorbye H, Collette L, et al. Final results of the EORTC Intergroup randomized phase III study 40983 [EPOC] evaluating the benefit of peri-operative FOLFOX4 chemotherapy for patients with potentially resectable colorectal cancer liver metastases. J Clin Oncol 2007; 25(18 suppl):2s (Abstract LBA5).